Retinal Vein Occlusion
Conditions
Brief summary
This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30 BRVO and 30 CRVO, respectively) are enrolled in the study. The study included a fixed treatment period (3 months) and a PRN period (6 months). In the fixed treatment period patients will receive 3 consecutive monthly intravitreal of 0.5 mg Conbercept. In the PRN period, patients are monthly visited and retreatment will be needed according to the retreatment criteria pre-specified.
Interventions
BIOLOGICALConbercept
intravitreal injection of 0.5 mg Conbercept
Sponsors
Chengdu Kanghong Biotech Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Ability and willingness to provide signed Informed Consent Form. 2. Age ≥ 18, both male and female。 3. Ocular Inclusion Criterion (Study Eye): * Diagnosis of Foveal center-involved macular edema due to RVO (both CRVO and BRVO) within 6 months. * Best corrected visual acuity (BCVA) letter score in the study eye of ≤ 73（Snellen equivalents 20/40）. * Central retinal thickness by OCT in the study eye ≥ 320 μm.
Exclusion criteria
1. Brisk afferent pupillary defect. 2. History of any anti-VEGF treatment in the study and/or system within 6 months before enrollment, and/or in the fellow eye within 3 month. 3. History of intraocular and/or peri-ocular corticosteroid use in the study eye within 3 months, and/or history of use steroids systemic (p.o., i.m., i.v.) within 1 month. 4. Any active infection involving the ocular including blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis in either eye. 5. Any inflammatory cells detected in the anterior chamber and/or vitreous in the study eye. 6. Presence of non-RVO disease, in the opinion of the investigator, might cause macular edema, such as AMD (wet or dry), diabetes retinopathy, uveitis etc. 7. Neovascular change in the study eye and/or neovascularization of the iris or neovascular glaucoma in study eye at baseline. 8. Patients with substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by equal or more than 3 lines or medicine or surgery treatment are needed in the study eye within 4 months. 9. Patients diagnosed with systemic immune diseases and any uncontrolled clinical disease. 10. Pregnant or nursing women. 11. Patients need to exclude in the opinion of investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline in BCVA | 3-month |
Secondary
| Measure | Time frame |
|---|---|
| Mean change from baseline in BCVA | baseline to 9-month |
| Mean change from baseline in central retinal thickness | baseline to 9-month |
| Mean injection times | baseline to 9-month |
| Mean change from baseline in Macular edema volume and other anatomical character in the study eye | baseline to 9-month |
| Rate of adverse event | 3-month and 9-month |
Countries
China
Outcome results
None listed